ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase
Status:
Completed
Trial end date:
2016-03-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate if intramuscular PEG-asparaginase administered
either at six or two week intervals from day 92 until 8 months from diagnosis for patients
with non-HR ALL will result in equal probability of Event Free Survival
Phase:
Phase 3
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborator:
Nordic Society for Pediatric Hematology and Oncology